Dr. Brad McGregor is the Director of Clinical Research at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and the latest Section Editor for the Muscle Invasive Bladder Cancer (MIBC) knowledge hub for GU Oncology Now. With a distinguished career that began with an unconventional path through military medicine, Dr. McGregor has become a leading figure in GU oncology. His work has contributed to significant advancements in the field, including his involvement in the pivotal EV-201 trial, which led to the FDA approval of enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC). Dr. McGregor’s innovative research continues to shape the future of GU oncology, ...
Expert Interviews
Advertisement
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.